|
| Author/year | Design | | Intervention | Main outcomes |
|
|
Masclans et al., 1998 [32] | RCT, single-centre | 21 | LCT/MCT (versus LCT versus placebo),
12 hr | ↑CO, O2 consumption and delivery
= Pulmonary haemodynamics and arterial O2 tension |
|
| Suchner et al., 2001 [33] | RCT (crossover) | 18 | Rapid (6 hr) versus slow (24 hr) fat emulsion,
LCT/MCT | Rapid: ↑P/T, pulmonary shunt and CO; ↓PVR, SVR, and PaO2/FIO2 |
|
| Faucher et al., 2003 [34] | RCT (crossover) | 18 | LCT/MCT (versus LCT),
6 hr | Transitory ↑PaO2/FIO2 |
|
| Gadek et al., 1999 [36] | RCT, multicentre | 146 | EPA + GLA, 4–7 days | ↑PaO2/FIO2
↓Days of MV and UCI LOS |
|
| Sabater et al., 2008 [37] | RCT, single-centre | 16 | LCT/MCT/ω-3 (versus LCT),
12 hr | = Oxygenation, haemodynamics |
|
| Sabater et al., 2011 [38] | RCT, single-centre | 16 | LCT/MCT/ω-3 (versus LCT),
12 hr | ↓LTB4, TXB2, 6-keto-PG during infusion |
|
| Singer et al., 2006 [39] | RCT, single-centre | 100 | EPA + GLA (versus standard), 14 days | Transitory ↑PaO2/FIO2
= Mortality |
|
| Pontes-Arruda et al., 2011 [40] | RCT, multicentre | 115 | EPA + GLA (versus standard),
7 days | ↓Severe sepsis and SS
↓Cardiac and respiratory failure
↓Days of MV and UCI LOS
= 28-day mortality |
|
| Rice et al., 2011 [41] | RCT, multicentre | 272 | EPA + GLA supplementation (versus standard) twice daily | ↓MV-free days, ICU-free days, nonpulmonary organ failure-free days
Stopped for futility |
|
| Stapleton et al., 2011 [42] | RCT, multicentre | 90 | EPA + DHA (versus placebo),
14 days | ↑Serum EPA
= IL-8 in BALF, organ failure score, MV-free days, ICU-free days, and 60-day mortality |
|
| Grau-Carmona et al., 2011 [43] | RCT, multicentre | 132 | EPA + GLA (versus standard) | = Oxygenation and organ failures |
|
| Elamin et al., 2012 [44] | RCT, multicentre | 17 | EPA + GLA (versus standard),
7 days | ↓LIS, ICU LOS, 28-day multiorgan dysfunction score
= Mortality |
|
